VA's Aduhelm Restrictions: Big Symbolism But Small Impact?

Biogen is ‘pleased’ access will be available through exceptions process in formulary restrictions though the US veterans agency does not expect there will be ‘significant’ interest among its clinicians in prescribing through that process. Price was not deciding factor, agency says.

VA Takes A Tough Stance On Covering Aduhelm

In another blow to the potential uptake of Biogen, Inc.’s and Eisai Co., Ltd.'s controversial new drug for Alzheimer’s disease, the US Department of Veterans Affairs has decided it will not cover Aduhelm on its centralized drug formulary or allow the manufacturers to promote the drug to VA clinicians because it has an unfavorable risk/benefit profile.

“We did not add it to the VA national formulary based on the risk of significant adverse drugs events and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet